ArticleFrontiers in physiology2019
Dynamic Targeting in Cancer Treatment.
Article in Frontiers in physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- A Spatiotemporal Image-Guided Model of Radiopharmaceutical Transport in Heterogeneous Vasculature Prostate Tumor: A Computational Analysis of Key Parameters in Lutetium-177 PSMA Therapy.Annals of biomedical engineering · 2026Article
- How do vibration stimulation frequencies affect the nonlinear dynamics and mechanical characterization of breast cancer cells?Biochemistry and biophysics reports · 2026Article
- Growth rate-driven modelling suggests that phenotypic adaptation drives drug resistance in BRAFV600E-mutant melanoma.Communications biology · 2026Article
- Multilayer network approaches to omics data integration in digital twins for cancer research.Frontiers in systems biology · 2026Review
- Article
- Spatial cumulant models enable spatially informed treatment strategies and analysis of local interactions in cancer systems.Journal of mathematical biology · 2023Article
- Recent Advancement in Anticancer Compounds from Marine Organisms: Approval, Use and Bioinformatic Approaches to Predict New Targets.Marine drugs · 2022Review
- SYNPRED: prediction of drug combination effects in cancer using different synergy metrics and ensemble learning.GigaScience · 2022Article
- Optimal Strategy and Benefit of Pulsed Therapy Depend On Tumor Heterogeneity and Aggressiveness at Time of Treatment Initiation.Molecular cancer therapeutics · 2022Article
- Deepening into Intracellular Signaling Landscape through Integrative Spatial Proteomics and Transcriptomics in a Lymphoma Model.Biomolecules · 2021Article
- Article
- A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden.Nature biomedical engineering · 2021Article
- Image-guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- A Multiscale Agent-Based Model of Ductal Carcinoma In Situ.IEEE transactions on bio-medical engineering · 2020Article
- A systems approach to clinical oncology uses deep phenotyping to deliver personalized care.Nature reviews. Clinical oncology · 2020Review
- Mathematical Modeling to Address Challenges in Pancreatic Cancer.Current topics in medicinal chemistry · 2020Article
- Development of a Physiologically-Based Mathematical Model for Quantifying Nanoparticle Distribution in Tumors.Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
With the advent of personalized medicine, design and development of anti-cancer drugs that are specifically targeted to individual or sets of genes or proteins has been an active research area in both academia and industry. The underlying motivation for this approach is to interfere with several pathological crosstalk pathways in order to inhibit or at the very least control the proliferation of cancer cells. However, after initially conferring beneficial effects, if sub-lethal, these artificial perturbations in cell function pathways can inadvertently activate drug-induced up- and down-regulation of feedback loops, resulting in dynamic changes over time in the molecular network structure and potentially causing drug resistance as seen in clinics. Hence, the targets or their combined signatures should
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.